Biosimilars
34 results
Applied filters
Preparing to use denosumab 120mg biosimilar
11 August 2025Biosimilars of denosumab 120mg (Xgeva) are expected soon. We offer general information and implementation advice.
Understanding biological and biosimilar medicines
1 August 2025Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions
Biosimilar and key generic medicines – September 2025 update
11 September 2025An update about biosimilar and key generic medicines to support system mobilisation.
Understanding data exclusivity and market protection
11 July 2025Data exclusivity and market protection periods prevent generic or biosimilar competition for at least 10 years after the originator medicine is licensed.
Understanding patents
11 July 2025Patents allow the inventor a finite period of monopoly in exchange for publicising the idea. We explain how they work with respect to medicines.
Understanding biosimilar and generic market entry
11 July 2025New medicines have several protections against competition. Other factors influence availability of biosimilars or generics after loss of exclusivity.
Preparing to use aflibercept 2mg biosimilar
4 July 2025Aflibercept 2mg biosimilars for use in ophthalmology are expected in December 2025 for NHS use. We offer general information and implementation advice.
Preparing to use golimumab biosimilar
21 May 2025Golimumab biosimilars are expected soon. We offer general information and implementation advice.
Good governance when implementing ustekinumab biosimilar
2 August 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for ustekinumab biosimilars
2 August 2024Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.